Bruker Announces Agreement to Acquire Neurescence Inc., Bolstering Neuroscience Research Portfolio

Rhea-AI Summary

Bruker Corporation (Nasdaq: BRKR) has signed a definitive agreement to acquire Neurescence Inc., known for its innovative Multiscopes™ technology that allows simultaneous multi-region optical neuroimaging. Neurescence's Chromatone™ system, which minimizes weight on animals, enhances the investigation of neuron functions. This acquisition strengthens Bruker's portfolio in animal imaging and expands its capabilities in neuroresearch. Financial terms of the deal were not disclosed, but the acquisition is expected to leverage synergies with Bruker's existing products, positioning the company as a leader in this field.

Positive

• Acquisition of Neurescence enhances Bruker's product offerings in optical neuroimaging.
• Chromatone™ technology allows simultaneous imaging of multiple brain regions, increasing research capabilities.
• Synergies with existing Bruker products can drive innovation and market expansion.

Negative

• None.

Delivers Simultaneous Multi-Region Neural Imaging of Free-Behaving Animals

BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) today announced the signing of the definitive agreement to purchase 100% of the shares of Neurescence Inc., an innovative provider of ultralight fiber-bundle Multiscopes^™ for simultaneous multi-region, optical functional neuroimaging. Neurescence’s flagship product Chromatone^™ moves illumination and detection hardware off the animal head. This enables simultaneous imaging and stimulation of three sub-types of neurons in up to four regions for flexible investigation of the central nervous system with single-neuron resolution in naturalistic behavior. This platform creates strong synergies with Bruker’s existing Ultima multiphoton solutions and newly acquired Inscopix head-mounted miniscopes. Financial details of the agreement were not disclosed.

“Our differentiated system provides a viable means of performing multi-region-of-interest investigation with minimal weight impact to subject animals,” said Dr. Yasaman Soudagar, Co-Founder and CEO of Neurescence. “Now, with Bruker, we can greatly increase the worldwide reach of this technology to enable researchers to gain deeper knowledge of neural network functions.”

“Along with our recent addition of Inscopix, this acquisition bolsters Bruker’s position as the leading provider of freely behaving animal imaging and photostimulation,” added Dr. Mark R. Munch, Bruker NANO Group President. “Neurescence’s extremely flexible and light-weight fiber-bundle Multiscope^™ with off-animal approach has great potential to address diversified research needs and future trends, opening the door to advanced imaging modalities.”

About Neurescence Inc.
Based in Toronto, Canada, Neurescence was founded in 2015 by a team of scientists dedicated to developing better methods for studying the central nervous system. The company holds recent patents for simultaneous multi-region optical imaging and stable detachable fiber-lens connectors with a focus lock mechanism. Neurescence’s Chromatone system enables in vivo calcium imaging and optogenetics across multiple brain and spinal cord regions, at single-cell resolution. The use of a detector that is off-animal enables both higher frame rate capture and the use of more sensitive cameras. Neurescence combines this novel optical imaging technology with machine learning to overcome critical challenges in neuroresearch. Learn more at www.neurescence.com.

About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005434/en/

Investors:

Justin Ward

Senior Director, Investor Relations & Corporate Development

T: +1 (978) 663-3660 x1479

E: Investor.Relations@bruker.com

Media:

Stephen Hopkins

Content Marketing Manager

T: +1 (520) 741-1044 x1022

E: steve.hopkins@bruker.com

Source: Bruker Corporation

FAQ

What did Bruker Corporation announce regarding Neurescence Inc.?

Bruker Corporation announced the acquisition of Neurescence Inc., which specializes in ultralight fiber-bundle Multiscopes™ for optical neuroimaging.

How will the acquisition of Neurescence impact Bruker Corporation?

The acquisition is expected to enhance Bruker's position in animal imaging and provide advanced capabilities in neuroresearch.

What are the key technologies involved in the acquisition?

Neurescence's Chromatone™ technology enables simultaneous imaging of multiple brain regions with minimal weight impact.

When was the acquisition of Neurescence Inc. announced by Bruker?

The acquisition was announced on the date of the press release, but the exact date is not specified.